Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Salmonella enterica serotype Typhi antigen refers primarily to the surface antigens present on the bacterium Salmonella enterica serovar Typhi, which causes typhoid fever. The most clinically significant of these is the Vi (virulence) capsular polysaccharide antigen, but other important antigens include O (somatic) and H (flagellar) antigens. The Vi capsule acts as a major virulence factor by reducing inflammatory responses, inhibiting phagocytosis, and increasing resistance to oxidative killing. Detection of antibodies against these antigens is used for diagnosis, and purified Vi polysaccharide has been developed into an effective vaccine.
Antibody production against S. Typhi antigens
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salmonella enterica serotype Typhi antigen.